|
Humanization of a mouse anti-OX40 monoclonal antibody to treat cancer
|
5R43CA159797-02
|
$106,505
|
$53,253
|
TRIGLIA, DENNIS
|
AGONOX, INC.
|
|
Nemours Community Clinical Oncology Program
|
3U10CA176879-01S1
|
$89,460
|
$895
|
SANDLER, ERIC
|
ALFRED I. DU PONT HOSP FOR CHILDREN
|
|
2014 AUA Urological Oncology Research Symposium: ""Progress in Translational Uro
|
1R13CA186649-01
|
$6,000
|
$1,980
|
GIAMBARRESI, LEO
|
AMERICAN UROLOGICAL ASSOCIATION
|
|
Bay Area Tumor Institute CCOP
|
3U10CA045461-24S1
|
$81,028
|
$1,621
|
FEUSNER, JAMES
|
BAY AREA TUMOR INSTITUTE
|
|
Virginia Mason Community Clinical Oncology Program
|
3U10CA035192-29S1
|
$86,403
|
$3,456
|
NICHOLS, CRAIG
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Mechanism of Acquired Resistance to VEGF-R Antagonists in RCC
|
5K08CA138900-05
|
$169,560
|
$169,560
|
BHATT, RUPAL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Novel treatment strategies for enhancing sunitinib response in renal cell cancer
|
5R21CA176912-02
|
$183,549
|
$183,549
|
LIBERMANN, TOWIA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Pathway Specific Imaging in VHL Deficient Renal Cancer
|
5R01CA152330-04
|
$344,543
|
$344,543
|
SETH, PANKAJ
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
The pVHL/Jade-1/beta-catenin axis in renal cancer
|
3R01CA079830-13S1
|
$66,893
|
$66,893
|
COHEN, HERBERT
|
BOSTON MEDICAL CENTER
|
|
The pVHL/Jade-1/beta-catenin axis in renal cancer
|
5R01CA079830-13
|
$310,590
|
$310,590
|
COHEN, HERBERT
|
BOSTON MEDICAL CENTER
|
|
VHL tumor suppressor gene and the initiation of renal cell carcinoma
|
5R01CA109860-10
|
$318,644
|
$318,644
|
HSU, TIEN
|
BOSTON MEDICAL CENTER
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S5
|
$110,177
|
$1,102
|
KACHNIC, LISA
|
BOSTON MEDICAL CENTER
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
1U10CA180821-01
|
$10,540,919
|
$210,818
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-01S1
|
$228,063
|
$4,561
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-01S2
|
$264,661
|
$5,293
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-01S3
|
$16,838
|
$337
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Molecular Pathogenesis of the Hamartoma Syndromes
|
5P01CA120964-08
|
$1,727,206
|
$138,176
|
KWIATKOWSKI, DAVID
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Computerized Monitoring Tool for MR-Guided Cryoablation
|
5R01CA152282-05
|
$428,193
|
$428,193
|
TUNCALI, KEMAL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Proteo-genomic Discovery, Prioritization and Verification of Cancer Biomarkers
|
5U24CA160034-04
|
$3,023,578
|
$755,895
|
CARR, STEVEN
|
BROAD INSTITUTE, INC.
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-24S1
|
$74,051
|
$2,962
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-24S2
|
$29,166
|
$1,167
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-24S3
|
$145,188
|
$5,808
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
5P30CA043703-24
|
$4,748,649
|
$189,946
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
1U10CA180853-01
|
$1,188,450
|
$29,711
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
A novel soluble receptor-based therapy for Kidney Cancer
|
1R21CA178157-01A1
|
$172,369
|
$172,369
|
WELFORD, SCOTT
|
CASE WESTERN RESERVE UNIVERSITY
|
|
A Novel Antibody Drug Conjugate for Metastatic Renal Cancer Treatment
|
1R43CA183223-01
|
$224,734
|
$224,734
|
PRUDENT, JAMES
|
CENTROSE, LLC
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
1U10CA180884-01
|
$400,000
|
$80,000
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
1U10CA180886-01
|
$26,616,497
|
$1,596,990
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-01S1
|
$79,593
|
$4,776
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-01S2
|
$208,457
|
$12,507
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-01S3
|
$229,232
|
$13,754
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-01S4
|
$1,163,256
|
$69,795
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-01S5
|
$1,543,656
|
$92,619
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-01S6
|
$265,465
|
$15,928
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-01S7
|
$3,000,000
|
$180,000
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Cadherin-regulated apoptosis and survival signaling in epithelial cells
|
5R01CA142647-04
|
$350,219
|
$350,219
|
HANSEN, STEEN
|
CHILDREN'S HOSPITAL CORPORATION
|
|
Novel Therapeutic Targets For Calcineurin Inhibitor-Induced And mTOR-Mediated Can
|
5R21CA172946-02
|
$185,570
|
$185,570
|
PAL, SOUMITRO
|
CHILDREN'S HOSPITAL CORPORATION
|
|
THE ROLE OF LIN28B IN WILMS TUMOR
|
1F31CA186444-01
|
$34,996
|
$34,996
|
YERMALOVICH, ALENA
|
CHILDREN'S HOSPITAL CORPORATION
|
|
Delaware/Christiana Care Community Clinical Oncology Program
|
3U10CA045418-27S1
|
$237,321
|
$4,746
|
GRUBBS, STEPHEN
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
Sunitinib Modulation of Cancer Immunotherapy
|
5R01CA150959-05
|
$501,600
|
$501,600
|
FINKE, JAMES
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Regulation of MDSC function and trafficking
|
5R01CA168488-02
|
$365,525
|
$182,763
|
FINKE, JAMES
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Germline KLLN Alterations in PTEN Mutation Negative Cowden Syndrome
|
5F30CA168151-02
|
$47,676
|
$23,838
|
NIZIALEK, EMILY
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Columbia University Medical Center Minority-Based Community Clinical Oncology Pro
|
3U10CA167791-02S1
|
$73,416
|
$1,468
|
KELLY, KARA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Columbus Community Clinical Oncology Program (Columbus CCOP)
|
3U10CA035261-30S1
|
$135,525
|
$5,421
|
KUEBLER, PHILIP
|
COLUMBUS COMMUNITY CLINICAL ONCOLOGY PRG
|
|
Cancer Center Support Grant
|
3P30CA006516-49S1
|
$118,825
|
$1,188
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-49S2
|
$75,000
|
$750
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-49S3
|
$12,500
|
$125
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
5P30CA006516-49
|
$10,827,666
|
$108,277
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
|
1U10CA180867-01
|
$1,302,200
|
$48,833
|
BURSTEIN, HAROLD
|
DANA-FARBER CANCER INST
|
|
The von Hippel-Lindau Tumor Suppressor Protein:Roles in Cancer and Oxygen Sensing
|
5R01CA068490-19
|
$283,515
|
$283,515
|
KAELIN, WILLIAM
|
DANA-FARBER CANCER INST
|
Total relevant funding to Kidney Disease for this search: $40,404,868
|